TickerFacts.

Compare

Ocular Therapeutix, Inc vs Lexicon Pharmaceuticals, Inc. vs Integrated Biopharma Inc vs Nektar Therapeutics

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearOcular Therapeutix, Inc
OCUL		Lexicon Pharmaceuticals, Inc.
LXRX		Integrated Biopharma Inc
INBP		Nektar Therapeutics
NKTR
Year ended2025-12-312025-12-312025-06-302025-12-31
Revenue$51.95M$49.80M$54.35M$55.23M
Revenue growth (YoY)-18.5%+60.2%+8.0%-43.9%
Gross margin87.3% (computed)n/a10.2%n/a
Operating margin-519.8%-98.2%3.7%-253.7%
Net margin-511.9%-101.1%1.5%-297.1%
Net income-$265.94M-$50.34M$808.0K-$164.08M
EPS (Diluted)-$1.42-$0.14$0.03-$9.73
Operating cash flow-$204.88M-$67.85M$2.06M-$208.51M
Free cash flow-$216.89M-$67.85M$1.87M-$208.68M
Cash & equivalents$737.06M$34.33M$3.62M$15.12M
Total assets$808.06M$184.99M$24.90M$280.41M
Total liabilities$153.75M$77.45M$4.58M$190.57M
Shareholders' equity$654.31M$107.54M$20.32M$89.83M
Return on year-end equity-40.6%-46.8%4.0%-182.6%
Shares outstanding215.93M365.85M31.06M20.38M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearOcular Therapeutix, IncLexicon Pharmaceuticals, Inc.Integrated Biopharma IncNektar Therapeutics
Latest$51.95M
Ended 2025-12-31		$49.80M
Ended 2025-12-31		$54.35M
Ended 2025-06-30		$55.23M
Ended 2025-12-31
1 year earlier$63.72M
Ended 2024-12-31		$31.08M
Ended 2024-12-31		$50.32M
Ended 2024-06-30		$98.43M
Ended 2024-12-31
2 years earlier$58.44M
Ended 2023-12-31		$1.20M
Ended 2023-12-31		$50.67M
Ended 2023-06-30		$90.12M
Ended 2023-12-31
3 years earlier$51.49M
Ended 2022-12-31		$139.0K
Ended 2022-12-31		$56.25M
Ended 2022-06-30		$92.06M
Ended 2022-12-31
4 years earlier$43.52M
Ended 2021-12-31		$298.0K
Ended 2021-12-31		$63.56M
Ended 2021-06-30		$101.91M
Ended 2021-12-31